Roche’s Genentech bets on radiopharmaceuticals in partnership with PeptiDream
20 Sep 2023
Radiation TherapyAcquisitionDrug ApprovalLicense out/inClinical Study
Dive Brief:
In a deeper move into radiopharmaceuticals, Roche’s Genentech unit will collaborate with the Japan-based biotechnology company PeptiDream to develop “peptide-radioisotope” conjugates, PeptiDream said Wednesday.
PeptiDream will use its peptide discovery platform system to identify and develop candidates for potential cancer drugs against targets Genentech will focus on. Under the deal, PeptiDream will receive $40 million up front and is eligible to receive up to $1 billion in milestone payments.
The new deal expands upon an initial partnership formed between the two companies in 2015, which resulted in Genentech licensing its platform system technology the following year. The deal was expanded again in 2018.
Dive Insight:
Interest in radiopharmaceuticals has been taking off ever since Novartis won drug approval of a drug it acquired with the buyout of the biotech Endocyte. Other big drugmakers such as Merck & Co. and Bristol Myers Squibb are acquiring a stake in the new space that, while enticing, still faces several obstacles through development.
Targeted radiation drugs such as Novartis’ drugs Pluvicto and Lutathera are more attractive than typical radiation therapy because the medicines can target cancer cells while sparing surrounding healthy cells. However, manufacturing and supplying radioisotopes is a long and complex process. Earlier candidates struggled to take off after development, and Novartis faced initial problems with supply.
PeptiDream has been in the radiopharma space for some time. The company, founded in 2006, said it sells and markets radiopharmaceutical products in Japan through its wholly-owned subsidiary PDRadiopharma.
Its work has caught the eye of other pharmaceutical companies and has several other partnerships under its belt including with Bristol Myers, Novartis and Astellas Pharma. San Diego-based biotech RayzeBio, which went public last week, has also partnered with PeptiDream and developed two targeted radiopharmaceuticals.
In the Genentech deal, PeptiDream will take the lead on the preclinical development of radioisotope drug conjugates. Once identified, Genentech will then take over on development and commercialization.
PeptiDream retains its right to develop and commercialize its drug conjugates in Japan.
'
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.